Gal-Invent Korlátolt Felelősségű Társaság v. Vanessa Research Holdings, Inc., Norman Gray, Dmitry Kravtsov, and Maria Gray

CourtDistrict Court, D. Connecticut
DecidedMarch 12, 2026
Docket3:24-cv-01787
StatusUnknown

This text of Gal-Invent Korlátolt Felelősségű Társaság v. Vanessa Research Holdings, Inc., Norman Gray, Dmitry Kravtsov, and Maria Gray (Gal-Invent Korlátolt Felelősségű Társaság v. Vanessa Research Holdings, Inc., Norman Gray, Dmitry Kravtsov, and Maria Gray) is published on Counsel Stack Legal Research, covering District Court, D. Connecticut primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Gal-Invent Korlátolt Felelősségű Társaság v. Vanessa Research Holdings, Inc., Norman Gray, Dmitry Kravtsov, and Maria Gray, (D. Conn. 2026).

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF CONNECTICUT

GAL-INVENT KORLÁTOLT FELELŐSSÉGŰ TÁRSASÁG, Plaintiff, Case No. 3:24cv1787(MPS) v.

VANESSA RESEARCH HOLDINGS, INC., NORMAN GRAY, DMITRY KRAVTSOV, and MARIA GRAY,

Defendants.

RULING ON NORMAN GRAY’S MOTION TO DISMISS Gal-Invent Korlátolt Felelősségű Társaság (“Gal-Invent”) brings this diversity action against Vanessa Research Holdings, Inc. (“Vanessa”), and certain of its officers, Norman Gray, Dmitry Kravtsov, and Maria Gray. Gal-Invent’s claims arise out of “a fraud perpetrated by Vanessa and its top executives.” ECF No. 1 ¶ 1. The complaint asserts claims for breach of contract, fraud, forgery, unjust enrichment, statutory theft, aiding and abetting fraud, violation of section 10(b) of the Securities Exchange Act of 1934, and the Connecticut Uniform Securities Act, or in the alternative, the Delaware Securities Act. Defendant Norman Gray, proceeding pro se, has filed a motion to dismiss. ECF No. 28. For the reasons that follow, the motion is denied. I. Factual Background The following is taken from the allegations of the complaint, which I accept as true for the purposes of this ruling. Gal-Invent “is a Hungarian-incorporated company” with an office in Budapest. ECF No. 1 ¶ 15. Defendant Vanessa, a pharmaceutical research and development company, is a Delaware corporation with its principal place of business and corporate headquarters in Hamden, Connecticut. Id. ¶¶ 2, 16. Defendant Norman Gray was the former CEO of Vanessa and resided in Hamden, Connecticut, until June 3, 2024, when he entered the custody of the United States Bureau of Prisons. Id. ¶ 17. Defendant Maria Gray, Norman’s daughter, is Vanessa’s Chief Medical Officer and a member of the Board of Directors and resides in Hamden. Id. ¶¶ 8, 18. Defendant Dmitry Kravtsov, the President of Vanessa, resides in Cheshire, Connecticut. Id. ¶ 16.

Gal-Invent was the majority owner of a company called “Hungaro-Gal,” a successful mid- sized pharmaceutical company in Hungary. Id. ¶ 22. Norman Gray approached Gal-Invent indicating that Vanessa was looking to expand its operations and that Hungaro-Gal presented a seemingly perfect fit for acquisition by Vanessa. Id. ¶ 23. Gray held himself out as an MIT- educated Ph.D. worth hundreds of millions of dollars and a successful biomedical entrepreneur with a lengthy track record of successful companies. Id. ¶ 26. He indicated to Gal-Invent’s representatives that Vanessa was funded by his family’s trust, PG Trust, which consisted of “hundreds of millions of dollars.” Id. ¶ 24. Gal-Invent visited Vanessa’s and Gray’s offices in Hamden, Connecticut in 2019. Id.

Gray indicated that Vanessa was in expansion mode and that if Gal-Invent agreed to a purchase deal, Vanessa would make significant improvements to Hungaro-Gal’s facilities. Id. ¶ 25. Gray and Kravtsov represented to Gal-Invent that an outside investor was interested in a significant investment in Vanessa. Id. After extensive negotiations, discussions, and a due diligence investigation of Hungaro- Gal by Vanessa, Vanessa and the owners of Hungaro-Gal, including Gal-Invent, reached an agreement for Vanessa to purchase Hungaro-Gal. Id. ¶ 6. On October 7, 2019, Vanessa purchased nearly all shares (97.4%) of Hungaro-Gal pursuant to a stock purchase agreement by and between Gal-Invent, Dr. Klara Tiszavari, and Tamas Csirisznyak, as sellers, and Vanessa Research Holdings Inc. and Vanessa Research Magyarorszag Felelossegu Tarsagag, as purchasers (the “Hungaro-Gal SPA”). Id. As consideration for Gal-Invent’s shares of Hungaro-Gal, Vanessa did not compensate Gal-Invent in cash but rather issued Gal-Invent 100,000 shares of Vanessa common stock at a par value of $.001 per share pursuant to a separate stock purchase agreement (the “Vanessa SPA”). Id. ¶ 7. Gal-Invent and Vanessa further entered into a Put Option Agreement (the “Original POA”),

which gave Gal-Invent the option to sell back its shares of Vanessa to Vanessa for a minimum price of $3,000,000 (“Guaranteed Put Purchase Price”) at any time between September 30, 2021 through November 30, 2021 (the “Exercise period”). Id. ¶ 29. The Original POA purported to be guaranteed by PG Trust. Id. ¶ 7. Kravtsov confirmed Gray’s successful track record to induce Gal-Invent to accept the Vanessa SPA and Original POA in lieu of a cash payment. Id. Before the November 30, 2021 deadline of the exercise period, Gray told Gal-Invent that Vanessa needed more time to be able to satisfy Vanessa’s obligations in the event Gal-Invent exercised its option. Id. ¶ 31. When Gal-Invent responded that it was disinclined to enter an amended agreement, the defendants emailed Gal-Invent forged and/or fraudulent documents

purporting to show that PG Trust, the guarantor of the original POA, was a legitimate and well- funded entity that could cover Vanessa’s obligations. Id. The documents included a HSBC bank letter indicating that PG Trust had an investment portfolio “well in excess of £300,000,000.” Id. ¶ 32. On November 26, 2021, Gal-Invent and Vanessa entered into an Amended POA. Id. ¶ 30. The Amended POA extended the exercise period to January 31, 2022. Id. ¶¶ 30, 35. Gal-Invent would not have agreed to the Amended POA but for the assurances by the defendants that PG Trust was flush with money and could easily guarantee the full $3,000,000 purchase price. Id. ¶ 33. On January 19, 2022, within the timeframe set forth in the Amended POA, Gal-Invent notified Vanessa that it was exercising its right to sell back its 100,000 shares of Vanessa common stock for the Guaranteed Put Purchase Price of $3,000,000. Id. ¶ 40. Vanessa was thereby obligated to repurchase the stock from Gal-Invent within 30 days. Id. ¶ 9. In the event Vanessa did not do so, PG Trust was obligated to do so. Id. Vanessa and PG Trust, however, failed to repurchase Vanessa’s 100,000 shares of common stock. Id. In “numerous emails,” Norman Gray confirmed to Gal-Invent that Vanessa would honor its obligation to make payment. Id. ¶ 42. In

February and March of 2023, Kravtsov e-mailed Gal-Invent valuations of Vanessa that indicated that Vanessa was worth millions. Id. ¶ 44. But to date, neither Vanessa nor PG Trust have performed as required under the Amended POA by buying back the 100,000 shares for the put purchase price of $3,000,000. Id. ¶ 45. As it turns out, Gray was not a multimillionaire scientist and entrepreneur with a Ph.D. from MIT, as he claimed, and Vanessa was not worth hundreds of millions of dollars, as he and Kravtsov claimed. Id. ¶ 13. As for PG Trust, it is a sham. Id. ¶ 10. It either does not exist or does not have the money claimed in the fraudulent HSBC Bank letter. Id. The HSBC letter purporting to show that PG Trust had “daily operational balance [...] in excess of £500,000 and Investment

portfolio well in excess of £300 million” was a forgery. Id. ¶¶ 10, 32. The valuations of Vanessa were inflated and likely based on bogus assumptions provided by Vanessa. Id. ¶ 51. Unbeknownst to Gal-Invent, at the time Gray and Kravtsov were making these representations, Gray was under federal indictment in the Southern District of New York for wire fraud for which he was convicted in 2024. Id. ¶¶ 46, 51. II. Discussion Although Gray does not invoke the federal rule1, the Court construes his motion as a motion

1 The defendant’s motion is a spartan one page, ten sentence document entitled “Motion to Dismiss Based on Lack of Jurisdiction.” ECF No. 28. It states in toto: 1. Plaintiff is a registered entity in Hungary; 2. The subject of this action is a Hungarian registered company; to dismiss for improper venue under Fed. R. Civ. P. 12

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Phillips v. Audio Active Ltd.
494 F.3d 378 (Second Circuit, 2007)
City of New York v. Cyco. Net, Inc.
383 F. Supp. 2d 526 (S.D. New York, 2005)
Cold Spring Harbor Laboratory v. Ropes & Gray LLP
762 F. Supp. 2d 543 (E.D. New York, 2011)
Marcus v. American Contract Bridge League
562 F. Supp. 2d 360 (D. Connecticut, 2008)
MacCallum v. New York Yankees Partnership
392 F. Supp. 2d 259 (D. Connecticut, 2005)
Indymac Mortgage Holdings, Inc. v. Reyad
167 F. Supp. 2d 222 (D. Connecticut, 2001)
Daniel v. American Board of Emergency Medicine
428 F.3d 408 (Second Circuit, 2005)

Cite This Page — Counsel Stack

Bluebook (online)
Gal-Invent Korlátolt Felelősségű Társaság v. Vanessa Research Holdings, Inc., Norman Gray, Dmitry Kravtsov, and Maria Gray, Counsel Stack Legal Research, https://law.counselstack.com/opinion/gal-invent-korlatolt-felelossegu-tarsasag-v-vanessa-research-holdings-ctd-2026.